PERNIX THERAPEUTICS HOLDINGS, INC. PTX Cash Flow

Pernix therapeutics holdings, inc. (PTX)

CashFlow / TTM

Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Net loss
-	0	-66,263	-	-	-163,593	-173,116	-169,590	-165,179	-149,481	-150,577	-148,315	-74,468	-75,419	-49,418	-35,286	-33,691	-27,823	-27,266	-25,635	-20,810	-15,257	-10,512	-1,410	3,865	6,130	8,563	8,347	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
409	354	367	370	393	405	681	704	698	698	406	361	320	269	250	331	445	574	678	672	650	579	441	324	192	106	101	97	0	0	0
Amortization of intangibles
0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	6,651	5,289	3,947	2,878	2,740	2,544	2,346	2,205	0	0	0
Amortization of deferred financing costs
3,759	3,724	3,626	3,296	2,992	2,708	2,455	2,440	2,593	2,551	2,542	2,730	2,903	2,949	2,813	2,333	1,566	1,124	1,493	1,295	0	0	0	-	-	-	-	-	-	-	-
Accretion expense
5,248	5,045	5,136	5,279	5,239	5,007	4,534	4,057	3,505	3,422	3,157	2,286	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
PIK Interest
0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest accretion of notes receivable
-	-	-	-	-	-	-	-	-	-	-	-127	-176	-216	-254	-292	-329	-285	-200	-114	0	0	0	-	-	-	-	-	-	-	-
Deferred income benefit
-	-	-	-	-	-	-	-200	16,929	14,194	9,840	6,746	-16,568	-13,178	-8,563	-11,753	-17,630	-25,705	-28,000	-22,516	-11,548	-4,513	-2,772	-1,836	-376	-758	-1,295	-2,273	0	0	0
Deferred income tax (benefit) provision
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Loss on disposal of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-26	0	0	0	-	-	0	0
Stock compensation expense
1,884	1,972	2,146	2,491	2,573	1,883	1,994	2,718	3,596	5,098	5,542	5,944	5,717	5,252	4,778	4,686	3,930	3,543	3,282	2,049	2,268	2,455	2,703	2,654	2,312	1,991	1,568	1,283	0	0	0
Fair market value change in contingent consideration
-1,246	-362	-1,128	-1,045	-2,350	-2,718	-5,804	-11,652	-5,500	-9,612	-5,640	-138	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Expense for stock options issued in exchange for services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	119	241	372	520	548	570	603	643	685	715	689	500	312	0	0	0
Fair market value change in derivative liability
-124	-152	-382	-47	-2,153	-1,898	-1,787	-8,935	-6,829	-17,565	-26,109	-19,315	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of put right
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-
Change in fair value of contingent consideration and put right
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-805	-283	-283	0	0	0	0	-	-	-	-
Loss on sale of PML (including impairment)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,659	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
(Increase) decrease in operating assets, net of effects of acquisitions:
Loss from the operations of the joint venture
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	240	362	463	724	814	0	0	0
Impairment charge
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-
Accounts receivable
-9,538	-9,971	6,006	-5,412	3,596	-3,201	-21,285	-11,009	-16,345	1,523	6,915	17,082	8,744	23,672	12,991	18,480	28,541	-3,922	1,333	-12,163	-9,765	-2,302	792	3,886	-3,906	4,545	5,085	5,843	0	0	0
Income tax receivable
-384	-351	-612	-1,291	-2,922	-6,578	-6,176	-5,321	-5,433	3,983	3,002	4,145	8,701	3,019	8,045	6,592	0	0	0	-	-	-	-	-	-	-	-	-	-	-	0
Income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,471	-3,457	-3,376	-1,335	0	0	0	-	-	-	-
Inventory
-6,290	-3,424	-2,037	-2,379	-152	-1,211	-4,383	-2,260	-2,379	628	-31	-444	-48	-2,598	1,335	-1,880	-4,153	-3,965	-4,404	-7,406	-4,062	-3,893	-2,966	650	-1,447	2,882	943	2,115	0	0	0
Prepaid expenses and other assets
-6,830	-5,511	-5,887	-3,830	7,773	1,560	2,439	533	-104	-5,993	-3,012	-2,471	-3,405	3,824	1,916	2,144	1,758	1,228	1,202	2,180	3,001	1,110	1,212	180	589	249	-495	274	0	0	0
Increase (decrease) in operating liabilities, net of effects of acquisitions:
Accounts payable and accrued expenses
571	-4,746	-2,255	-2,115	-3,934	-2,731	-17,177	-7,960	-15,342	2,383	17,782	6,682	10,951	13,105	6,740	12,161	12,731	-10,183	-808	-3,398	-1,826	3,207	-1,919	-1,843	-1,696	1,961	1,458	739	0	0	0
Accrued allowances
496	-1,719	4,445	-4,652	1,899	-7	-6,673	-1,717	-1,603	3,548	10,746	10,074	23,672	17,912	12,733	18,318	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Accrued allowances
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4,948	-4,798	3,209	1,544	-806	4,408	3,506	7,960	0	0	0
Interest payable
528	-381	-847	-518	-747	-871	-397	-1,006	-37	-1,027	2,461	2,291	7,055	12,600	4,187	10,012	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Other liabilities
-2,710	-2,200	-2,027	-2,228	-2,226	-2,099	-2,180	-2,628	-4,702	-4,885	-6,724	-4,973	-7,223	-7,006	-1,150	-4,672	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-22,116	-4,838	-5,406	-5,939	-2,829	-4,892	-13,982	-16,501	-26,744	-25,612	976	-14,749	21,254	9,169	-4,030	8,896	-20,357	-16,194	-15,159	-6,531	-12,026	-8,902	-4,244	-1,926	8,807	7,325	9,214	9,397	0	0	0
Cash flows from investing activities:
Acquisitions
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Acquisitions of licenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Acquisition of Cypress
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Purchase of software and equipment
152	113	19	18	25	38	760	984	1,147	1,435	1,216	1,212	1,645	1,484	1,285	1,177	579	668	507	528	0	0	0	-	-	-	-	-	-	-	0
Purchase of equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Net cash used in investing activities
-66,931	2,333	1,981	1,982	-25	-38	-1,343	-1,567	-3,539	-4,227	-84,352	-84,348	-84,882	-332,374	-250,030	-249,922	-247,410	20,145	23,716	23,386	-28,307	-52,946	-62,921	-64,897	-14,231	-10,086	-4,577	-2,175	0	0	0
Cash flows from financing activities:
Net proceeds from revolving credit facility
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	1,000	0	0	0
Proceeds from issuance of Convertible Notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	65,000	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-
Cash acquired in connection with acquisition of Somaxon
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,881	0	0	0	-	-	-	-	-	-	-	-
Payments on contracts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,700	2,250	4,413	4,110	3,540	2,290	290	260	1,230	0	0	0
Payments on Treximet Secured Notes
5,373	10,072	10,072	17,511	17,511	18,310	18,310	20,406	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment on financing costs
222	13,808	13,808	13,587	0	0	0	-	-	-	-	-	-	-	-	14,149	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-
Net payments on credit facilities
-	-	-	-	-	-	-	-1,000	4,000	6,059	3,342	7,655	-8,783	-5,188	5,610	-9,515	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Payments on mortgages and capital leases
35	34	42	52	82	88	84	77	66	62	53	44	28	13	19	46	70	108	134	144	0	0	0	-	-	-	-	-	-	-	-
Tax benefit on stock-based awards
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-404	210	210	194	147	0	0	0	-	-	-	-	-	-	-	-
Tax benefit on stock-based awards
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	315	162	228	270	137	0	0	0
Shares withheld for the payment of taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,109	-775	-774	-812	-230	-208	-208	-134	0	0	0	0	-	-	-	-
Proceeds from issuance of stock in additional offering, net of issuance costs of $846 for the year ended December 31, 2012
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23,751	23,751	43,010	21,660	19,259	0	0	0
Payments on mortgages and capital leases
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-121	0	0	0	-	-	-	-
Principal payments received on notes receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	113	0	0	0
Proceeds from issuance of common stock, net of tax and costs
-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	0	-	-	-	0	-	-	-	-	289	0	0	0
Shares withheld for the payment of taxes
-	-	-	-	-	-	-	23	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments on term loan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Stock issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
86,215	8,089	7,630	402	1,574	-9,936	1,416	-1,692	1,617	-7,785	101,093	120,377	104,386	329,245	217,138	260,234	274,505	47,791	21,034	-24,231	12,988	20,388	54,225	55,295	14,897	36,634	21,610	19,069	0	0	0
Net decrease in cash and cash equivalents
-2,730	5,584	4,205	-3,555	-1,280	-14,866	-13,909	-19,760	-28,666	-37,624	17,717	21,280	40,758	6,040	-36,922	19,208	6,738	51,742	29,590	-7,376	-27,345	-41,460	-12,941	-11,528	9,473	33,873	26,247	26,291	0	0	0
Cash paid for income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	1,405	2,224	2,505	2,482	5,711	6,596	8,415	8,911	0	0	0
Acquisition of product licenses - contract payable balance
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Accrued 2011 bonus paid in unrestricted common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0
Interest paid during the period
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	922	2,094	907	200	143	186	194	177	0	0	0
Acquisition of license - contract payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-870	-870	-870	630	0	0	0	-	-	-	-
Acquisition of license and supply agreement - contract payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Acquisition of Cypress and Somaxon - Purchase price adjustment (see Note 4)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,250	0	0	0	0	-	-	-	-
Acquisition of Somaxon - Fair value of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23,840	23,840	23,840	0	0	0	0	-	-	-	-